131 results about "PEGylation" patented technology

The disclosure provides method of treating cancer in a patient with ATM-deficient or ATR-deficient tumors, comprising safely and efficaciously administering to the patient PLXO38, a long lasting-PEGylated prodrug of the topoisomerase I inhibitor. The disclosure further provides combination therapies of PLXO38 with inhibitors of the DNA damage response (DDR).

The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and / or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.

The invention relates to lipid nanoparticles for fish in-vivo skin gene editing and application of the lipid nanoparticles, and belongs to the technical field of fish gene editing. The lipid nanoparticle for fish in-vivo skin gene editing comprises a gene editing element and a lipid layer, wherein the lipid layer wraps the surface of the gene editing element; the gene editing element is a CRISPR (clustered regularly interspaced short palindromic repeats) / Cas9 (CRISPR associated protein 9) ribonucleoprotein compound or nucleic acid for coding the compound; the lipid nanoparticle carrier comprises ionizable cationic lipid, auxiliary lipid, cholesterol, pegylated lipid and permanent cationic lipid, and the lipid nanoparticle carrier comprises the following components in parts by mole: 15 parts of ionizable cationic lipid, 25-30 parts of auxiliary lipid, 30 parts of cholesterol, 3 parts of pegylated lipid and 7 parts of permanent cationic lipid. The formula is high in pertinence, high in editing efficiency, simple, convenient and safe to operate and wide in application prospect.

This description provides formulations for a pharmaceutical product comprising a PEGylated CBS protein having the amino acid sequence SEQ ID NO: 1. Dosages and dosage regimens are provided for the treatment of homocystinuria in a subject in need. In addition, dosages and dosage regimens are also provided for reducing homocysteine ​​(Hcy) levels or increasing cysteine ​​(Cys) and / or cystathionine (Cth) levels in a subject in need.

Formulations of gas-filled microvesicles comprising a ligand, which may advantageously be used in methods for separating cells or biological materials. The formulations comprise a phospholipid and a suitable mixture of a pegylated phospholipid and of a pegylated phospholipid comprising a ligand.

Provided herein is an antibody-drug conjugate (ADC) especially a PEGylated mono- or bispecific antibody hydroxyl-bearing drug conjugate prepared with site-specific conjugation to provide homogeneous conjugate with high potency and low toxicity. The disclosure also relates to a method for the preparation of the antibody hydroxyl-bearing drug conjugate, a composition comprising the antibody hydroxyl-bearing drug conjugate, and the use thereof in treating diseases.

Provided is a method for improving the stability of urate oxidase. The inventors have discovered that combining an active ingredient urate oxidase or chemically modified urate oxidase with a stabilizer xanthine through a non-covalent bond can significantly improve the in vivo and in vitro stability of urate oxidase and chemically modified urate oxidase in the form of a tetramer, thereby effectively improving the stability of urate oxidase.

Provided herein are targeting compounds (e.g., a compound of Formula I, a stereoisomer thereof, a tautomer thereof, and / or a pharmaceutically acceptable salt thereof), lipid nanoparticle (LNP) compositions comprising such targeting compounds and the use thereof. The LNP compositions described herein may further comprise one or more selected from ionizable lipids, PEG-lipids, phospholipids, and structural lipids.

This invention relates to lipid nanoparticles for in vivo skin gene editing in fish and their applications, belonging to the field of fish gene editing technology. The lipid nanoparticles for in vivo skin gene editing in fish comprise: a gene editing element and a lipid layer, wherein the lipid layer coats the surface of the gene editing element; the gene editing element is a CRISPR / Cas9 ribonucleoprotein complex or a nucleic acid encoding the complex; the lipid nanoparticle carrier comprises ionizable cationic lipids, auxiliary lipids, cholesterol, polyethylene glycol-modified lipids, and permanently cationic lipids, and by molar weight, the proportions are 15 parts ionizable cationic lipids, 25-30 parts auxiliary lipids, 30 parts cholesterol, 3 parts polyethylene glycol-modified lipids, and 7 parts permanently cationic lipids. The formulation of this invention is highly targeted, has high editing efficiency, is simple and safe to operate, and has broad application prospects.

The application provides a reduction-responsive nano delivery system and application thereof in preparation of a drug for treating drug-resistant tumors, and belongs to the pharmaceutical field. The application constructs a reduction-responsive branched copolymer functionalized by pegylation and deoxycholic acid (DA) (referred to as: pegylated branched poly(HPMA-DA)), which can effectively encapsulate small molecule drugs to form a nano delivery system. Experiments prove that the nano delivery system can be taken up by tumor cells, has good tumor targeting, and exhibits excellent anti-tumor effect in tumor xenografts (CDX) derived from non-small cell lung cancer (NSCLC) chemoresistant cell lines and patient-derived xenograft mouse models (PDX). The pegylated branched poly(HPMA-DA) provided by the application has wide application prospect in preparation of a drug carrier, and the nano delivery system provided by the application has wide application prospect in preparation of a drug for treating cancer.

The invention relates to the technical field of cosmetics, in particular to a makeup removal composition, a preparation method thereof and a makeup removal product. The makeup removing composition is prepared from grease, polyhydric alcohol and an emulsifying agent according to the weight ratio of (10 to 20): (0.5 to 10): (2 to 10), the grease comprises one or more of first grease and second grease; the first grease comprises one or more of ether grease, alkane grease and ester grease; the second grease is selected from pegylated alkanoic acid glyceride compounds; the polyol comprises one or more of a first polyol and a second polyol; the first polyhydric alcohol comprises a diol compound; the second polyol comprises an alkyl glyceryl ether compound. The makeup removing composition and the makeup removing product have efficient makeup removing power and also have a water-based refreshing skin feeling.

The invention belongs to the field of biological medicine, and particularly relates to lipid nanoparticles for local drug delivery, a preparation method of the lipid nanoparticles and application of the lipid nanoparticles to preparation of anti-scar drugs. The lipid nanoparticle comprises a lipid carrier and nucleic acid wrapped by the lipid carrier, and the lipid carrier comprises the following components: an ionizable lipid, a permanent cationic lipid, a pegylated lipid, an auxiliary phospholipid and a sterol compound; the molar ratio of the ionizable lipid to the permanent cationic lipid to the pegylated lipid to the auxiliary phospholipid to the sterol compound is (25-45): (5-25): (1-2): (5-15): (35-40). In order to solve the problem of single administration of lipid nanoparticles in the prior art, the lipid nanoparticles are designed to be externally applied and applied for local administration through proportion regulation and control, so that the targeting property is improved, and the administration concentration is increased. Whole-body blood circulation is avoided, and toxic and side effects and off-target performance are reduced. Therefore, the dual purposes of synergism and toxicity reduction are achieved.

The invention relates to lipid nanoparticles containing an adjuvant for mucosal administration and a preparation method of the lipid nanoparticles. The lipid nanoparticles comprise total lipid, an adjuvant and an active ingredient, wherein the total lipid is composed of cationic lipid C12-200, non-cationic phospholipid, cholesterol and a derivative thereof, and pegylated lipid; wherein the adjuvant is selected from at least one of AS03, MF59, monophosphoryl lipid A, miniaturized monophosphoryl lipid A, ophiopogonin D, saponin QS21, QS7, QS17, QS18, CpG oligonucleotide, 2 '3'-ring GMP-AMP, 3 '3'-ring GMP-AMP, alpha GC, Trehalose-6, 6-dibehenate, cholera toxin B subunit and flagellin.

The invention relates to the technical field of skin care, and discloses a sustained-release composition containing azelaic acid composite lipidosome and application of the sustained-release composition in acne treatment and skin repair. Comprising a composite liposome, an encapsulated active component and a dispersion medium, the composite liposome is composed of a lipid bilayer, the lipid bilayer comprises phospholipid, cholesterol and pegylated phospholipid, and the phospholipid is a mixture of hydrogenated soybean phospholipid and dipalmitoyl phosphatidylcholine; the encapsulated active component comprises a fat-soluble component and a water-soluble component; the water-soluble components comprise a hamamelis virginiana leaf water extract and a herba portulacae extract; the dispersion medium is a phosphate buffer solution; by optimizing lipid composition, introducing surface modification and constructing a multi-layer release system, the invention aims to synergistically exert multiple effects of antibiosis, anti-inflammation, cutin regulation, red fading, repair and the like, and provides an efficient, mild and integrated solution for acne and sequelae skin problems thereof.

The invention discloses a skin implant, the skin implant is a freeze-drying agent, the freeze-drying agent is prepared from the following components in parts by weight: 2-15 parts of a PEG-PLA copolymer and 0.05-4.0 parts of hyaluronate, the PEG-PLA copolymer is prepared from a single-terminal hydroxyl polyethylene glycol compound and lactide through a polymerization reaction, and the hyaluronate is prepared from the following components in parts by weight: 1-10 parts of a cross-linking agent, 1-10 parts of a cross-linking agent, 1-10 parts of a cross-linking agent and 1-10 parts of a cross-linking agent. The mass ratio of the single-end hydroxyl polyethylene glycol to the lactide is (2.0-8.5): 1, and the molecular weight of the hyaluronate is 10-100 WDa. The skin implant provided by the invention has an excellent redissolution speed and can be quickly redissolved within 10 minutes, and the quick redissolution characteristic of the freeze-drying agent greatly facilitates clinical operation and shortens the preoperative preparation time.

The present invention relates to a lipid nanoparticle comprising: (a) an ionizable lipid; (b) a helper lipid; (c) a sterol; and (d) a PEGylated lipid, wherein: (i) the PEGylated lipid comprises a hydrocarbon chain comprising more than 14 C atoms; and / or (ii) the PEGylated lipid is at a concentration of at least 3 %mol.

The invention relates to lipid nanoparticles for delivering FSHR-siRNA as well as a preparation method and application of the lipid nanoparticles, and belongs to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: S1, dissolving ionizable cationic lipid, auxiliary lipid, cholesterol and pegylated lipid in an organic solvent to obtain an oil phase; the method comprises the following steps: dissolving FSHR-siRNA in a first buffer solution to obtain a water phase; and S2, mixing the oil phase and the water phase by adopting a microfluidic technology, diluting with a second buffer solution, and removing the organic solvent to obtain the lipid nanoparticles for delivering the FSHR-siRNA. The lipid nanoparticle has excellent transfection efficiency and relatively high stability, and by virtue of delivery of the FSHR-siRNA by virtue of the lipid nanoparticle, a series of difficulties faced by effective transcription and translation of the FSHR-siRNA in vivo can be effectively solved.

The present application provides a kind of polyglycolated ropivacaine derivative, with the structure of PEG-D p The PEG polyglycolated ropivacaine derivative described is significantly longer in analgesic duration compared to ropivacaine hydrochloride, and the analgesic effect of the double-end polyglycolated ropivacaine derivative is better than that of the four-arm or eight-arm polyglycolated ropivacaine derivative.

A composition includes a compound of Formula 1, a solvate thereof, or a salt thereof. A method for treating an inflammatory disease includes administering the compound to a subject in need thereof. The compound of Formula 1 can protect cells and reduce inflammation by removing reactive oxygen species and suppressing inflammatory cytokines in a non-toxic manner.

The present invention concerns methods comprising co-administration of pegfilgrastim and romiplostim for treatment of diseases and conditions characterized by low neutrophil levels (neutropenia) and / or low platelet levels (thrombocytopenia). The present invention concerns an enhanced effect on neutrophil levels and on platelet levels resulting from co-administration of pegfilgrastim and romiplostim. The present invention further concerns a method of treating a patient who has been exposed to radiation, which comprises administering romiplostim at a dose of about 1 to about 10 g / kg. The invention further concerns such methods wherein a single dose of romiplostim is administered to the patient and wherein romiplostim is administered about 24 hours or less after the radiation exposure. The invention further concerns treatment with romiplostim and pegfilgrastim for radiation exposure. Such methods relate to treatment of acute radiation syndrome and treatment to counteract the effects of radiation therapy and other sources of radiation exposure.

The present invention discloses a lipid nanoparticle (LNP) and its application, comprising cationic ionisable lipids, auxiliary lipids, ligand-modified PEGylated lipids, and cholesterol. The auxiliary lipids and ligand-modified PEGylated lipids target receptors on the surface of liver sinusoidal endothelial cells (LSECs). The LNPs enhance LSEC-specific uptake through a targeted design involving the lipid-specific interaction pathway.

Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.

The application provides a manufacturing method of a near-infrared light responsive gold nano coating intelligent cell culture container, and solves the problems of complex manufacturing process, long cycle, high cost, low efficiency, poor biocompatibility and poor stability of the existing near-infrared light responsive cell culture container. The hydrophilic treatment of the cell culture container (substrate) can increase the number of hydroxyl groups on the surface, thereby increasing the bonding force between the gold nano structure sputtering layer and the cell culture container, making it more stable. The methoxy polyethylene glycol thiol is used to make the gold nano structure polyethylene glycol, so that the PEG is fully combined with the gold nano structure through the mercapto-gold bond to enhance the biocompatibility. Then the polyethylene glycolated gold nano structure and the polypeptide solution are mixed, the concentration of RGD is controlled to make it as much as possible to be coupled with the gold nano structure, and the targeting of the combination with the target cells is enhanced.

The invention belongs to the technical field of biological medicine, and relates to a releasable pegylated sirolimus compound and application thereof. The invention provides a releasable PEGylated sirolimus compound. The compound can be self-assembled to form micelles, prepared into nanoparticles and targeted to immune cells, regulates the release behavior of drugs, reduces the system toxicity and prolongs the biological half-life period. And moreover, the sirolimus-hydrophilic PEG conjugate has a proper hydrophobic sirolimus end and a hydrophilic PEG chain end, can effectively release drugs in immune cells, and is a good carrier for preparing nanoparticles. The invention provides a releasable PEGylated sirolimus compound, a nano-drug and a pharmaceutical composition prepared from the releasable PEGylated sirolimus compound, and application of the releasable PEGylated sirolimus compound in preparation of drugs for reducing immune response.

The invention relates to HIF-1alpha siRNA lipid nanoparticles and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: S1, dissolving ionizable lipid, neutral lipid, cholesterol and pegylated lipid in an organic solvent to obtain an oil phase; the method comprises the following steps: dissolving HIF-1alpha siRNA in a first buffer solution to obtain a water phase; s2, mixing the oil phase and the water phase by adopting a micro-fluidic technology, diluting with a second buffer solution, removing the organic solvent, and concentrating to obtain the HIF-1alpha siRNA lipid nanoparticles, the targeted delivery of the HIF-1alpha siRNA is realized, so that the HIF-1alpha siRNA is effectively delivered to the rheumatoid arthritis diseased region through the delivery system to play a therapeutic role.